Frontlight ResearchEarly access
Chronic lymphocytic leukaemia trials in China
44 of 48 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- Beijing, Guangzhou, Nanchang, Tianjin
- Age
- 18 years and over
- People
- 332 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05091424 - Phase 4Taking peopleA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou, Tianjin, Ürümqi, Xuzhou, Zhengzhou
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - Phase 1/2Not yet taking people in ChinaCAR-T Immunotherapy Targeting CD19- ALL
- Where
- Shenzhen
- Age
- 6 months to 75 years
- People
- 100
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04016129 - Phase 1Taking peoplePhase Ib Clinical Study of Keynatinib
- Where
- Beijing, Chengdu, Shanghai
- Age
- 18 years and over
- People
- 75
- Run by
- Medolution Ltd.
See details and how to joinNCT04807881 - Phase 1/2Taking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Beijing, Guangzhou, Jinan, Tianjin, Zhengzhou
- Age
- 18 years and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - Phase 2Taking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Liuzhou, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - Phase 1/2Taking peopleA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Where
- Beijing, Guangzhou, Suzhou
- Age
- 18 years and over
- People
- 258 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00 - Phase 3Taking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Jining, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Shiyan, Suzhou, Taizhou, Tianjin, Wuhan, Wuxi, Xiamen, Xi'an, Xinxiang, Yangzhou
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - Phase 1/2Taking peopleTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Qingdao, Shanghai, Suzhou, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Zhengzhou
- Age
- 18 years and over
- People
- 146
- Run by
- BeOne Medicines
See details and how to joinNCT05294731 - Phase 1Taking peopleA Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Where
- Zhengzhou
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT07424833 - Phase 3Taking peopleA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Liuzhou, Nanchang, Nanjing, Nanning, Suzhou, Taiyuan, Tianjin, Ürümqi, Wuhan, Xi'an, Xuzhou, Zhengzhou
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01 - Phase 1/2Active, not recruitingA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Beijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 1/2Taking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Hangzhou, Shanghai
- Age
- 18 years and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - Phase 3Taking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Beijing, Binzhou, Changchun, Changsha, Chengdu, Dalian, Dazhou, Fuzhou, Guangzhou, Guiyang, Harbin, Jiangmen, Kunming, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taian, Taiyuan, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xining, Xuchang, Xuzhou, Zhengzhou
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - Phase 3Taking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Xi'an, Zhengzhou
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - Phase 2Not yet taking people in ChinaRituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
- Where
- Changsha, Guangzhou, Nanchang, Nanjing, Wuhan, Zhengzhou
- Age
- 18 years and over
- People
- 23
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07831395 - Phase 1/2CompletedStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Where
- Baoding, Bengbu, Chongqing, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Shenyang, Suzhou, Tianjin, Zhengzhou
- Age
- 12 years and over
- People
- 160 worldwide
- Run by
- Sellas Life Sciences Group
See details and how to joinNCT04588922 - Phase 3Taking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Ürümqi, Wuhan, Yiwu
- Age
- 18 years and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00 - Phase 3Not yet taking people in ChinaA Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Where
- Nanjing, Zhengzhou
- Age
- 18 years and over
- People
- 128
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07753369 - Phase 2Taking peopleA Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
- Where
- Nanjing
- Age
- 18 years and over
- People
- 75
- Run by
- Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07609823 - Phase 1/2Taking peopleA Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
- Where
- Tianjin
- Age
- 18 years and over
- People
- 92
- Run by
- Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07609862 - Phase 3Taking peopleA Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
- Where
- Bengbu, Changsha, Guangzhou, Shanghai, Tianjin, Wuhan, Zhanjiang, Zhengzhou
- Age
- 18 years and over
- People
- 344 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06319456 · EU 2024-514084-26-00 - Early phase 1Taking peopleA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- Where
- Tianjin, Zhengzhou
- Age
- 18 years to 75 years
- People
- 28
- Run by
- Grit Biotechnology
See details and how to joinNCT07205315 - Phase 2Not yet taking people in ChinaZanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL:Stop Trial 2.0
- Where
- Changsha, Jinan, Nanchang, Nanjing, Shenzhen, Tianjin, Zhengzhou
- Age
- 18 years and over
- People
- 60
- Run by
- Yi Shuhua
See details and how to joinNCT07682415 - Phase 2Taking peopleA Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 24
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07671378